MyMD Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Tables)

Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2019

This includes basing value on yields currently available on comparable securities of issuers with similar credit ratings.

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2)		Significant Unobservable Inputs (Level 3)
Marketable securities at March 31, 2019	$	-	$	4,477,525	$	-

Marketable securities at December 31, 2018	$	-	$	5,272,998	$	-

Schedule of Future Amortization Expense of Intangible Assets

The following is an annual schedule of approximate future amortization of the Company’s intangible assets:

Period	Amount
2019 (nine months)		30,006
2020		40,008
2021		40,008
2022		40,008
2023		40,008
Thereafter		43,371
	$	233,409

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	For the three months ended March 31,
	2019		2018
Stock Options		6,877		31,875
RSUs		374,481		-
Warrants		2,110,737		2,374,813
Total potentially dilutive shares		2,492,095		2,406,688